Johnson & Johnson (NYSE:JNJ) Shares Sold by Trilogy Capital Inc.

Trilogy Capital Inc. lessened its stake in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 3.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,590 shares of the company’s stock after selling 60 shares during the quarter. Trilogy Capital Inc.’s holdings in Johnson & Johnson were worth $282,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in JNJ. Family CFO Inc acquired a new stake in Johnson & Johnson in the 4th quarter valued at approximately $26,000. Steward Financial Group LLC purchased a new position in shares of Johnson & Johnson during the fourth quarter worth $34,000. Jackson Wealth Management LLC grew its stake in shares of Johnson & Johnson by 1.7% in the third quarter. Jackson Wealth Management LLC now owns 16,959 shares of the company’s stock valued at $40,000 after buying an additional 277 shares in the last quarter. Advocacy Wealth Management Services LLC raised its holdings in shares of Johnson & Johnson by 41.4% in the 1st quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company’s stock valued at $41,000 after buying an additional 67 shares during the period. Finally, Iron Horse Wealth Management LLC lifted its stake in Johnson & Johnson by 29.9% during the 4th quarter. Iron Horse Wealth Management LLC now owns 265 shares of the company’s stock worth $45,000 after acquiring an additional 61 shares in the last quarter. Institutional investors and hedge funds own 68.78% of the company’s stock.

In other news, EVP Kathryn E. Wengel sold 40,000 shares of the stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the sale, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at $12,336,803. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Robert J. Decker sold 8,462 shares of Johnson & Johnson stock in a transaction on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the completion of the transaction, the chief accounting officer now directly owns 15,473 shares in the company, valued at $2,785,140. The disclosure for this sale can be found here. Insiders have sold 78,161 shares of company stock worth $13,895,302 in the last quarter. Insiders own 0.35% of the company’s stock.

Several analysts have recently issued reports on the stock. The Goldman Sachs Group increased their price target on shares of Johnson & Johnson from $163.00 to $181.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 12th. Citigroup decreased their price target on shares of Johnson & Johnson from $210.00 to $205.00 in a research report on Tuesday, May 17th. Credit Suisse Group upped their price objective on Johnson & Johnson from $200.00 to $205.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 20th. Sanford C. Bernstein cut Johnson & Johnson from an “outperform” rating to a “market perform” rating and boosted their target price for the stock from $180.00 to $183.00 in a research note on Wednesday, March 16th. Finally, Raymond James increased their price target on Johnson & Johnson from $195.00 to $196.00 and gave the company an “outperform” rating in a research report on Wednesday, April 20th. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $190.50.

JNJ opened at $175.74 on Thursday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.14 and a current ratio of 1.39. Johnson & Johnson has a one year low of $155.72 and a one year high of $186.69. The company has a market cap of $462.44 billion, a P/E ratio of 23.68, a PEG ratio of 3.35 and a beta of 0.66. The business’s 50-day simple moving average is $177.66 and its 200-day simple moving average is $173.09.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its quarterly earnings results on Tuesday, April 19th. The company reported $2.67 EPS for the quarter, beating the consensus estimate of $2.60 by $0.07. The company had revenue of $23.43 billion for the quarter, compared to analyst estimates of $23.62 billion. Johnson & Johnson had a net margin of 20.90% and a return on equity of 36.59%. The firm’s revenue was up 5.0% on a year-over-year basis. During the same period in the prior year, the firm posted $2.59 earnings per share. As a group, analysts predict that Johnson & Johnson will post 10.23 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 7th. Shareholders of record on Tuesday, May 24th were issued a dividend of $1.13 per share. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.06. The ex-dividend date was Monday, May 23rd. This represents a $4.52 annualized dividend and a dividend yield of 2.57%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 60.92%.

About Johnson & Johnson (Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Want More Great Investing Ideas?

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.